BG60682B1 - Олеандомициноксими и метод за получаването им - Google Patents
Олеандомициноксими и метод за получаването им Download PDFInfo
- Publication number
- BG60682B1 BG60682B1 BG94079A BG9407991A BG60682B1 BG 60682 B1 BG60682 B1 BG 60682B1 BG 94079 A BG94079 A BG 94079A BG 9407991 A BG9407991 A BG 9407991A BG 60682 B1 BG60682 B1 BG 60682B1
- Authority
- BG
- Bulgaria
- Prior art keywords
- formula
- oleandomycin
- wavy line
- hydrogen
- compound
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- 238000000034 method Methods 0.000 title claims description 5
- 229960002351 oleandomycin Drugs 0.000 claims abstract description 28
- 239000004104 Oleandomycin Substances 0.000 claims abstract description 23
- RZPAKFUAFGMUPI-KGIGTXTPSA-N oleandomycin Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](C)C(=O)O[C@H](C)[C@H](C)[C@H](O)[C@@H](C)C(=O)[C@]2(OC2)C[C@H](C)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C RZPAKFUAFGMUPI-KGIGTXTPSA-N 0.000 claims abstract description 18
- RZPAKFUAFGMUPI-UHFFFAOYSA-N Oleandomycin Natural products O1C(C)C(O)C(OC)CC1OC1C(C)C(=O)OC(C)C(C)C(O)C(C)C(=O)C2(OC2)CC(C)C(OC2C(C(CC(C)O2)N(C)C)O)C1C RZPAKFUAFGMUPI-UHFFFAOYSA-N 0.000 claims abstract description 14
- 235000019367 oleandomycin Nutrition 0.000 claims abstract description 14
- 239000001257 hydrogen Substances 0.000 claims abstract description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 8
- 125000003700 epoxy group Chemical group 0.000 claims abstract description 5
- 239000004599 antimicrobial Substances 0.000 claims abstract 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 14
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 12
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 claims description 12
- 150000001875 compounds Chemical class 0.000 claims description 12
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 7
- 229910052757 nitrogen Inorganic materials 0.000 claims description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- 238000002955 isolation Methods 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims 3
- 239000003814 drug Substances 0.000 abstract description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 8
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 5
- 150000002596 lactones Chemical class 0.000 description 5
- 238000005160 1H NMR spectroscopy Methods 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 150000002923 oximes Chemical class 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 241000191938 Micrococcus luteus Species 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 150000002118 epoxides Chemical group 0.000 description 2
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 2
- -1 oleandomycin oximes Chemical class 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- XVMSFILGAMDHEY-UHFFFAOYSA-N 6-(4-aminophenyl)sulfonylpyridin-3-amine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=N1 XVMSFILGAMDHEY-UHFFFAOYSA-N 0.000 description 1
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 description 1
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000010531 catalytic reduction reaction Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
- C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Medicinal Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| YU00556/90A YU55690A (en) | 1990-03-21 | 1990-03-21 | Process for preparing oleandomycin oxime |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BG94079A BG94079A (bg) | 1993-12-24 |
| BG60682B1 true BG60682B1 (bg) | 1995-12-29 |
Family
ID=25550446
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BG94079A BG60682B1 (bg) | 1990-03-21 | 1991-03-20 | Олеандомициноксими и метод за получаването им |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US5268462A (sk) |
| EP (1) | EP0448035B1 (sk) |
| JP (1) | JP2763972B2 (sk) |
| CN (1) | CN1033645C (sk) |
| AT (1) | ATE132872T1 (sk) |
| BG (1) | BG60682B1 (sk) |
| CA (1) | CA2038629C (sk) |
| CZ (1) | CZ279898B6 (sk) |
| DE (1) | DE69116188T2 (sk) |
| DK (1) | DK0448035T3 (sk) |
| ES (1) | ES2084721T3 (sk) |
| GR (1) | GR3019113T3 (sk) |
| HR (1) | HRP920482B1 (sk) |
| HU (2) | HU207868B (sk) |
| PL (1) | PL166395B1 (sk) |
| RO (1) | RO111769B1 (sk) |
| RU (1) | RU2021281C1 (sk) |
| SI (1) | SI9010556B (sk) |
| SK (1) | SK279105B6 (sk) |
| UA (1) | UA26903C2 (sk) |
| YU (1) | YU55690A (sk) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2275459A2 (fr) * | 1974-06-21 | 1976-01-16 | Aries Robert | Nouveau derive de la rifamycine |
| US4063014A (en) * | 1975-06-12 | 1977-12-13 | Abbott Laboratories | 4"-O-sulfonyl erythromycin-9-O-oxime derivatives |
| US4069379A (en) * | 1976-07-08 | 1978-01-17 | Pfizer Inc. | Semi-synthetic oleandomycins |
| US4180654A (en) * | 1978-01-03 | 1979-12-25 | Pfizer Inc. | 4"-Deoxy-4"-acylamido derivatives of oleandomycin, erythromycin and erythromycin carbonate |
| US4336368A (en) * | 1981-04-20 | 1982-06-22 | Pfizer Inc. | 4 Deoxy-4-methylene oleandomycin and derivatives thereof |
| US4429116A (en) * | 1982-12-27 | 1984-01-31 | Pfizer Inc. | Alkylated oleandomycin containing compounds |
| JPS61103890A (ja) * | 1984-10-26 | 1986-05-22 | Taisho Pharmaceut Co Ltd | ６−０−メチルエリスロマイシンａ誘導体 |
-
1990
- 1990-03-21 SI SI9010556A patent/SI9010556B/sl not_active IP Right Cessation
- 1990-03-21 YU YU00556/90A patent/YU55690A/xx unknown
-
1991
- 1991-03-14 US US07/669,728 patent/US5268462A/en not_active Expired - Lifetime
- 1991-03-19 DE DE69116188T patent/DE69116188T2/de not_active Expired - Fee Related
- 1991-03-19 EP EP91104231A patent/EP0448035B1/en not_active Expired - Lifetime
- 1991-03-19 ES ES91104231T patent/ES2084721T3/es not_active Expired - Lifetime
- 1991-03-19 DK DK91104231.5T patent/DK0448035T3/da active
- 1991-03-19 AT AT91104231T patent/ATE132872T1/de not_active IP Right Cessation
- 1991-03-19 CA CA002038629A patent/CA2038629C/en not_active Expired - Fee Related
- 1991-03-20 HU HU91935A patent/HU207868B/hu not_active IP Right Cessation
- 1991-03-20 JP JP3130738A patent/JP2763972B2/ja not_active Expired - Fee Related
- 1991-03-20 CN CN91101710A patent/CN1033645C/zh not_active Expired - Fee Related
- 1991-03-20 UA UA4894988A patent/UA26903C2/uk unknown
- 1991-03-20 RU SU914894988A patent/RU2021281C1/ru not_active IP Right Cessation
- 1991-03-20 RO RO147197A patent/RO111769B1/ro unknown
- 1991-03-20 BG BG94079A patent/BG60682B1/bg unknown
- 1991-03-20 PL PL91289507A patent/PL166395B1/pl not_active IP Right Cessation
- 1991-03-21 CZ CS91768A patent/CZ279898B6/cs not_active IP Right Cessation
- 1991-03-21 SK SK768-91A patent/SK279105B6/sk unknown
-
1992
- 1992-09-25 HR HRP-556/90A patent/HRP920482B1/xx not_active IP Right Cessation
-
1995
- 1995-06-30 HU HU95P/P00609P patent/HU211574A9/hu unknown
-
1996
- 1996-02-28 GR GR960400535T patent/GR3019113T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HRP920482B1 (en) | 1998-12-31 |
| CS9100768A2 (en) | 1991-11-12 |
| RO111769B1 (ro) | 1997-01-30 |
| HU207868B (en) | 1993-06-28 |
| EP0448035A1 (en) | 1991-09-25 |
| ES2084721T3 (es) | 1996-05-16 |
| GR3019113T3 (en) | 1996-05-31 |
| CN1033645C (zh) | 1996-12-25 |
| DE69116188T2 (de) | 1996-09-05 |
| JPH04234896A (ja) | 1992-08-24 |
| SI9010556A (sl) | 1998-04-30 |
| PL166395B1 (pl) | 1995-05-31 |
| US5268462A (en) | 1993-12-07 |
| EP0448035B1 (en) | 1996-01-10 |
| RU2021281C1 (ru) | 1994-10-15 |
| SI9010556B (sl) | 1998-10-31 |
| UA26903C2 (uk) | 1999-12-29 |
| HU211574A9 (en) | 1995-12-28 |
| BG94079A (bg) | 1993-12-24 |
| HUT56848A (en) | 1991-10-28 |
| PL289507A1 (en) | 1992-03-09 |
| CA2038629C (en) | 1996-09-10 |
| CA2038629A1 (en) | 1991-09-22 |
| ATE132872T1 (de) | 1996-01-15 |
| CZ279898B6 (cs) | 1995-08-16 |
| DK0448035T3 (da) | 1996-05-20 |
| CN1054979A (zh) | 1991-10-02 |
| YU55690A (en) | 1990-12-31 |
| JP2763972B2 (ja) | 1998-06-11 |
| SK279105B6 (sk) | 1998-06-03 |
| DE69116188D1 (de) | 1996-02-22 |
| HRP920482A2 (en) | 1994-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK172636B1 (en) | 6-o-methylerythromycin a derivative | |
| US4474768A (en) | N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor | |
| RU2045533C1 (ru) | О-метильные производные азитромицина а, обладающие антибактериальной активностью, азитромицины в качестве промежуточных соединений для получения о-метильных производных азитромицина а и способ получения о-метильных производных азитромицина а | |
| CS241069B2 (en) | Method of 4"-epi-9-deoxo-9a-methyl-9a-aza-9a-homoerythromycine a preparation | |
| US4464527A (en) | Antibacterial 9-deoxo-9a-alkyl-9a-aza-9a-homoerythromycin A derivatives and intermediates therefore | |
| US4150220A (en) | Semi-synthetic 4"-erythromycin A derivatives | |
| HU211975A9 (en) | Derivatives of tylosin and 10,11,12,13-tetrahydrotylosin and their use in pharmaceuticals | |
| EP1304326B1 (en) | Single-step process for preparing 7,16-deoxy-2-aza-10-o-cladinosil-12-o-desosaminil-4,5-dihydroxi-6-ethyl-3,5,9,11,13,15-hexamethylbicycle (11.2.1)hexadeca-1(2)-en-8-ona and obtaining a new form of 9-desoxo-9a-methyl-9a-aza-9a-homoerythromycin a | |
| EP0009197A1 (en) | Aminoglycoside derivatives, process for their preparation and pharmaceutical compositions | |
| US4585759A (en) | Antibacterial derivatives of a neutral macrolide | |
| BG60682B1 (bg) | Олеандомициноксими и метод за получаването им | |
| Kurihara et al. | Cladinose analogues of sixteen-membered macrolide antibiotics I. Synthesis of 4-O-alkyl-l-cladinose analogues via glycosylation | |
| EP0508726A1 (en) | Novel process for the preparation of 9-deoxo-8a-aza-8a-homoerythromycin a and its 8a-alkyl derivatives | |
| IE46661B1 (en) | Erythromycin a derivatives | |
| RU2130936C1 (ru) | 9а-азалидные фрагменты макролидных антибиотиков класса азалидов, способ их получения и промежуточные соединения для их получения | |
| EP0508725A1 (en) | Novel process for the preparation of 8a-aza-8a-homoerythromycin cyclic iminoethers | |
| JPS5827799B2 (ja) | ４″−アミノ−オレアンドマイシン誘導体 | |
| JPS6340196B2 (sk) | ||
| CZ338297A3 (cs) | Nové polyhydroderiváty tylosinu a způsob jejich přípravy | |
| CA1128506A (en) | Semi-synthetic 4"-erythromycin a derivatives | |
| FI68404C (fi) | Foerfarande foer framstaellning av terapeutiskt anvaendbara 4"deoxi-4"-aminoerytromycin-a-derivat | |
| CS241099B2 (cs) | Způsob přípravy 4“-epi-9-deoxo-9a-methyl-9a-aza- -9a-bomoerythromycinu A |